Literature DB >> 28505637

In C difficile infection, adding IV bezlotoxumab to standard antibiotics reduced recurrence at 12 weeks.

Fred Arthur Zar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28505637     DOI： 10.7326/ACPJC-2017-166-10-053

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  1 in total

1.  Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection.

Authors:  Yuman Lee; Wai I Lim; Caitlyn I Bloom; Samantha Moore; Elizabeth Chung; Nino Marzella
Journal:  P T       Date:  2017-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.